Zhang Li-Jing, Zhan Li-Bin, Hang Tian-Yi, Luo Jin-Tong, Zhao Chun-Yan
Modern Research Laboratory of Spleen Visceral Manifestations Theory, School of Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
Center for Innovative Engineering Technology in Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine Shenyang 110847, China.
Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):988-1000. doi: 10.19540/j.cnki.cjcmm.20210907.401.
This study explored the mechanism of Shenling Baizhu Powder(SLBZP) in the prevention and treatment of type 2 diabetes from the perspective of flora disorder and chronic inflammation. Fifty rats were randomly divided into normal control group, model control group, low-dose SLBZP group, medium-dose SLBZP group, and high-dose SLBZP group, with 10 rats in each group. The rats of 5 weeks old were administrated by gavage with ultrapure water and different doses of SLBZP decoction. The basic indicators such as body weight and blood glucose were monitored every week, and stool and intestinal contents were collected from the rats of 9 weeks old for 16 S rRNA sequencing and metabolomic analysis. An automatic biochemical analyzer was used to measure the serum biochemical indicators, ELISA to measure serum insulin, and chipsets to measure leptin and inflammatory cytokines. The results showed that SLBZP reduced the body weight as well as blood glucose, glycosylated hemoglobin, and lipid levels. In the rats of 9 weeks, the relative abundance of Anaerostipes, Turicibacter, Bilophila, Ochrobactrum, Acinetobacter, and Prevotella decreased significantly in the model control group, which can be increased in the high-dose SLBZP group; the relative abundance of Psychrobacter, Lactobacillus, Roseburia and Staphylococcus significantly increased in the model control group, which can be down-regulated in the high-dose SLBZP group. The differential metabolites of intestinal flora included 4-hydroxyphenylpyruvic acid, phenylpyruvic acid, octanoic acid, 3-indolepropionic acid, oxoglutaric acid, malonic acid, 3-methyl-2-oxovaleric acid, and methylmalonic acid. Moreover, SLBZP significantly lowered the levels of free insulin, insulin resistance and leptin resistance in rats. The variations in the serum levels of interleukin 1β(IL-1β) and monocyte chemoattractant protein-1(MCP-1) showed that SLBZP could alleviate chronic inflammation in rats. In conclusion, SLBZP can regulate intestinal flora and metabolites and relieve chronic inflammation to control obesity and prevent type 2 diabetes.
本研究从菌群紊乱和慢性炎症的角度探讨了参苓白术散（SLBZP）防治2型糖尿病的机制。将50只大鼠随机分为正常对照组、模型对照组、低剂量SLBZP组、中剂量SLBZP组和高剂量SLBZP组，每组10只。对5周龄的大鼠灌胃给予超纯水和不同剂量的SLBZP水煎剂。每周监测体重、血糖等基本指标，并收集9周龄大鼠的粪便和肠内容物进行16S rRNA测序和代谢组学分析。采用自动生化分析仪检测血清生化指标，ELISA法检测血清胰岛素，芯片检测瘦素和炎性细胞因子。结果显示，SLBZP降低了体重以及血糖、糖化血红蛋白和血脂水平。在9周龄大鼠中，模型对照组中厌氧棒状菌属、Turicibacter菌属、嗜胆菌属、苍白杆菌属、不动杆菌属和普雷沃菌属的相对丰度显著降低，高剂量SLBZP组可使其增加；模型对照组中嗜冷杆菌属、乳杆菌属、罗氏菌属和葡萄球菌属的相对丰度显著增加，高剂量SLBZP组可使其下调。肠道菌群的差异代谢产物包括4-羟基苯丙酮酸、苯丙酮酸、辛酸、3-吲哚丙酸、氧代戊二酸、丙二酸、3-甲基-2-氧代戊酸和甲基丙二酸。此外，SLBZP显著降低了大鼠游离胰岛素、胰岛素抵抗和瘦素抵抗水平。血清白细胞介素1β（IL-1β）和单核细胞趋化蛋白-1（MCP-1）水平的变化表明，SLBZP可减轻大鼠的慢性炎症。综上所述，SLBZP可调节肠道菌群和代谢产物，缓解慢性炎症，从而控制肥胖并预防2型糖尿病。
